Fennec Pharmaceuticals announces first quarter 2023 financial results

Fennec Pharmaceuticals announces first quarter 2023 financial results


RESEARCH TRIANGLE PARK, NC, May 8, 2023 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. FENCFRXa commercial-stage specialty pharmaceutical company, today announced that it will release its first quarter 2023 financial results ahead of the opening of US financial markets on Thursday, May 11, 2023. Management will host a conference call and webcast that day to discuss the Company’s financial and operating results.

To participate in the conference call, please register https://register.event.com/register/BIda2814a842e34d0d825731a73c51d74d. Upon registration, a dial-in number and unique PIN are provided to join the call. To access the live webcast link, log on to www.fennepharma.com and go to the News & Events / Event Calendar page under the Investors & Media heading. Please connect to the company’s website at least 15 minutes prior to the conference call to allow time for the software download that may be required to listen to the webcast. A webcast replay of the conference call will also be archived on www.fennecpharma.com for thirty days.

About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of PEDMARKĀ® to reduce the risk of platinum-induced ototoxicity in pediatric patients. In addition, PEDMARK received FDA approval in September 2022 and has been granted orphan drug status in the United States. including reducing the risk of platinum chemotherapy-induced ototoxicity in humans. For more information, please visit www.fennecpharma.com.

For more information please contact:

Robert Andrade
Fennec Pharmaceuticals Inc.
+1 919-246-5299

Companies and media:
Lindsey Rocco
Elixir Health Public Relations

Source story

More to explorer